MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Medication for ADHD may help student outcomes

Back to psychology news Blogs list Cancer blog  


Subscribe To Psychology News RSS Feed  RSS content feed What is RSS feed?

Medication for ADHD may help student outcomes




In an 18-year-study on attention-deficit hyperactivity disorder (ADHD), Mayo Clinic scientists observed that therapy with prescription stimulants is linked to improved long-term academic success of children with ADHD. The Mayo Clinic results are the first population-based data to show stimulant drug treatment helps improve long-term school outcomes.

A related Mayo Clinic study reveals that in comparison to children without AD/HD, children with ADHD are at risk for poor long-term school outcomes such as low achievement in reading, absenteeism, repeating a grade, and dropping out of school. Both studies appear in the current edition of the Journal of Development & Behavioral Pediatrics, (http://www.jrnldbp.com).



Medication for ADHD may help student outcomes

Nearly 2 million children, or approximately 3 percent to 5 percent of young children in the United States, have ADHD. This disorder affects a childs ability to focus, concentrate and control impulsive behavior (http://www.nimh.nih.gov/publicat/adhd.cfm). This disorder is so common that most school classrooms have at least one child with clinically-diagnosed ADHD.

In this study, therapy with stimulant medicine during childhood was linked to more favorable long-term school outcomes, explains William Barbaresi, M.D., Mayo Clinic pediatrician and lead author of the reports.

Significance of the Mayo Clinic Studies
The two Mayo Clinic studies are the first population-based, long-term studies to investigate links between ADHD, school performance and factors that modify long-term school performance of children with ADHD. Scientists followed the children from the time they were born for, on average, 18 years. Of the more than 5,000 children reviewed, 370 (277 boys and 93 girls) were identified as having ADHD. Scientists matched them by age and gender to 740 children who did not meet the research criteria for having AD/HD. In addition to medical stimulants such as methylphenidate, also called Ritalin, the study examined the effects on school outcomes of maternal age, socioeconomic background, and special education services the students received.

School Outcome Results At a Glance
The children treated with stimulants typically began taking medicine in elementary school and received it for nearly three years -- on average, for 30.4 months. Results indicate:
  • Gender: Girls and boys with untreated ADHD were equally vulnerable to poor school outcomes -- and girls may be at risk for being under-identified as having ADHD, and therefore undertreated.
  • Reading: By age 13, on average, stimulant dose was modestly correlated with improved reading achievement scores.
  • Absenteeism: Both therapy with stimulants and longer duration of medicine were linked to decreased absenteeism.
  • Grade Retention: Children with A/HD who were treated with stimulants were 1.8 times less likely to be retained a grade than children with ADHD who were not treated.

Implications for Parents and Caregivers
Dr. Barbaresi believes that both studies provide the first solid evidence of the long-term negative academic performance linked to untreated ADHD -- as well as evidence for the best way to manage this problem. Dr. Barbaresi says, The finding that therapy with stimulant medications is linked to long-term improvement in school outcomes is significant. Previously, there was evidence that therapy.

with stimulant medications improved short-term academic performance, but there was no strong evidence that long-term outcomes are better with stimulant therapy. Our data can guide clinicians in their efforts to help children with ADHD succeed in school.

About the Studies
The Mayo Clinic team had a unique ability to identify groups of children with and without ADHD. Mayo Clinic has maintained a comprehensive communitywide medical records database since 1935, and scientists had access to all conditions, diagnoses and therapys the children received. In addition, Mayo obtained a research agreement with Independent School District #535, Rochester, Minn., including public and private schools, to access non-identifiable school records of all children born in Rochester between Jan. 1, 1976 and Dec. 31, 1982. This enabled scientists to correlate school performance of both children with and without ADHD in terms of medical conditions, maternal age, socioeconomic status and special education efforts.


Posted by: JoAnn    Source




Did you know?
In an 18-year-study on attention-deficit hyperactivity disorder (ADHD), Mayo Clinic scientists observed that therapy with prescription stimulants is linked to improved long-term academic success of children with ADHD. The Mayo Clinic results are the first population-based data to show stimulant drug treatment helps improve long-term school outcomes.

Medicineworld.org: Medication for ADHD may help student outcomes

Acute bacterial meningitis| Alzheimer's disease| Carpal tunnel syndrome| Cerebral aneurysms| Cerebral palsy| Chronic fatigue syndrome| Cluster headache| Dementia| Epilepsy seizure disorders| Febrile seizures| Guillain barre syndrome| Head injury| Hydrocephalus| Neurology| Insomnia| Low backache| Mental retardation| Migraine headaches| Multiple sclerosis| Myasthenia gravis| Neurological manifestations of aids| Parkinsonism parkinson's disease| Personality disorders| Sleep disorders insomnia| Syncope| Trigeminal neuralgia| Vertigo|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.